Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX | BCRX Message Board Posts


BioCryst Pharmaceuticals Inc.

  BCRX website

BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  12750 of 12775  at  7/1/2021 4:49:09 PM  by

moegrabbedmythumb

The following message was updated on 7/1/2021 4:52:20 PM.

 In response to msg 12748 by  kokopelli
view thread

Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX

   It looks like Kalvista's therapy (Phase 3 trials not yet started) is for treatment after a suspected attack arises and measures efficacy over a 12 hour period after the attack ensues.  I'd much rather avoid the attack in the first place.  Perhaps Kalvista's therapy can serve as a common sense backup should someone on Orladeyo have an attack.  


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1  
   Views: 0 [10]
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...